Neuronetics (STIM) Q1 2026 Earnings Transcript

Neuronetics reported Q1 revenue of $34.5 million, up 8% year over year, with U.S. clinic revenue rising 15% to $21.5 million and NeuroStar system shipments up 10% to 34 units. Profitability improved modestly as the net loss narrowed to $10.8 million from $12.7 million and adjusted EBITDA improved to negative $6.6 million, while management reaffirmed 2026 guidance for $160 million-$166 million in revenue and flat-to-positive operating cash flow in the second half. Offsetting the better top line, gross margin fell 230 bps to 46.9%, cash declined to $19 million, and management continues to evaluate strategic alternatives, including a possible separation of NeuroStar and Greenbrook.

Analysis

The key read-through is that the business is becoming more optionality-driven than headline-revenue-driven. Near-term, the more durable signal is not the top-line beat but the combination of lower opex, improving cash burn, and a CEO willing to reprice the commercial model; that trio usually matters more for a small-cap medtech than one quarter of utilization noise. If the new go-to-market pilots lift system placements even modestly, the operating leverage could show up fast because the installed base and clinic network already exist.

The second-order effect is that Greenbrook is evolving from a pure utilization story into a reimbursement and workflow story. That favors incumbents with infrastructure and hurts smaller TMS competitors that lack a scalable benefits-investigation and clinic ops backbone; it also raises the probability that the “best” path to value is some form of structural separation, because the market will likely assign very different multiples to a hardware/software-like NeuroStar asset versus a clinic services asset with lower margin but higher growth optionality. The Compass angle is important, but investors should treat it as a long-dated call option rather than a 2026 earnings driver.

The contrarian point: consensus may be underestimating how much of the current weakness is self-inflicted and reversible, not secular. Weather and uneven ad spend are not a thesis, but they do not explain away the underpenetration of the addressable market; the bigger issue is commercial execution discipline. If the new CEO can improve utilization at the same time he broadens pricing/menu choice, this could re-rate before revenue inflects, especially if Q2 shows the promised normalization.

Key Decisions for Investors

• Long STIM into the next 4-8 weeks only on confirmation of pilot readouts or Q2 acceleration; target a 20-30% rerating if the market starts to price a credible path to positive H2 cash flow, but cut if burn stays above ~$5M/quarter.
• Pair trade: long STIM / short a weaker-capitalized TMS or depression-treatment peer without integrated clinic infrastructure; the thesis is that reimbursement and workflow scale become more valuable as coverage broadens.
• Buy CMPS as a long-dated call option on regulatory optionality, not as an earnings trade; size small and use 6-12 month horizon, because approval/reimbursement timing remains the gating risk.
• For event-driven accounts, consider short-dated STIM calls or call spreads only after a volume-confirming quarter; the CEO’s commercial pilots create upside convexity, but execution risk remains high if placements do not improve.
• Avoid chasing STIM on cash-balance headlines alone; if the stock rallies into the next print without evidence of sustained utilization recovery, fade strength because balance-sheet relief is necessary but not sufficient.